5-hydroxymethylcytosine has been researched along with Thyroid Carcinoma, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kondo, T; Mochizuki, K; Oishi, N; Vuong, HG | 1 |
| Astvatsaturyan, K; Fan, X; Lai, J; Peralta-Venturina, M; Seok, JY | 1 |
2 other study(ies) available for 5-hydroxymethylcytosine and Thyroid Carcinoma, Anaplastic
| Article | Year |
|---|---|
Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations.
Topics: 5-Methylcytosine; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Mutation; Promoter Regions, Genetic; Telomerase; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2020 |
TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Topics: 5-Methylcytosine; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Biomarkers, Tumor; Camptothecin; Cell Adhesion Molecules; Feasibility Studies; Humans; Immunoconjugates; Immunohistochemistry; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Mutation; Patient Selection; Predictive Value of Tests; Prognosis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms | 2021 |